Clinical trial
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After…
NCT00048386 · Malcolm Brenner, Other · Completed
Key facts
| NCT number | NCT00048386 |
|---|---|
| Title | Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy |
| Official title | A Pilot Study of Gene Modified Autologous Neuroblastoma Vaccine for the Post-Chemotherapy Treatment of High-Risk Neuroblastoma |
| Acronym | CYCHE2 |
| Lead sponsor | Malcolm Brenner, Other |
| Collaborators | Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | autologous neuroblastoma vaccine |
| Enrollment | 13 |
| Start date | Nov 1, 1999 |
| Primary completion | Dec 1, 2004 |
| Completion | Oct 1, 2009 |
| First posted | Nov 1, 2002 |
| Last update posted | Jul 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: